Injectable, gelable and degradable system for protein delivery in partnership with Mannin

与 Mannin 合作的可注射、可凝胶和可降解的蛋白质输送系统

• 批准号: 570781-2021
• 负责人: Sheardown, HeatherHD
• 金额: $ 20.35万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=747091
• 关键词: Injectable; gelable; degradable; system; protein

The goal of this partnership is to create a drug delivery system for a new treatment that is physician and patient friendly for use in a glaucoma application. If successful, this will help alleviate the direct and indirect costs associated with glaucoma while growing the national biomanufacturing capabilities within Canada. Mannin Research has a number of biologically-based molecules that have shown preliminary potential for treating eye diseases and conditions, particularly glaucoma. However, the nature of these compounds leads to the potential for degradation, making appropriate delivery methods critical to their successful application. The goal of this proposal is to develop a delivery system for Mannin's formulation that is suitable for a glaucoma treatment. At McMaster, through the 20/20 NSERC Ophthalmic Materials Research Network and the ORF-funded C20/20 Innovation Hub, we have established an international reputation for the development and validation of new delivery methods for getting drugs into the eye using a team approach. Multidisciplinary projects involving polymer development, drug release and biological characterization as well as biological validation of the delivery system require teams with broad expertise and project management. All members of the team have expertise in the development of ophthalmic delivery systems; the team approach will capitalize on the strengths of each of the members (polymer science and chemistry, drug delivery validation, in vitro and in validation) to ensure a successful outcome. Through previous researcher collaborations, Mannin and the network members have worked on other applications. This existing relationship allows us to execute quickly on the research goals outlined in this proposal.

此次合作的目标是为青光眼应用中医生和患者友好的新疗法创建药物输送系统。如果成功，这将有助于减轻与青光眼相关的直接和间接成本，同时提高加拿大的国家生物制造能力。 Mannin Research 拥有许多基于生物的分子，这些分子已显示出治疗眼部疾病和病症（尤其是青光眼）的初步潜力。然而，这些化合物的性质导致了降解的可能性，因此适当的递送方法对其成功应用至关重要。该提案的目标是为 Mannin 的制剂开发一种适合青光眼治疗的输送系统。在麦克马斯特，通过 20/20 NSERC 眼科材料研究网络和 ORF 资助的 C20/20 创新中心，我们在开发和验证使用团队方法将药物输送到眼睛的新输送方法方面建立了国际声誉。涉及聚合物开发、药物释放和生物表征以及递送系统的生物验证的多学科项目需要具有广泛专业知识和项目管理的团队。团队所有成员均拥有眼科输送系统开发方面的专业知识；该团队方法将利用每个成员的优势（聚合物科学和化学、药物输送验证、体外和体内验证）以确保取得成功的结果。通过之前的研究人员合作，曼宁和网络成员已经开发了其他应用程序。这种现有的关系使我们能够快速执行本提案中概述的研究目标。